BR112015024920A2 - associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas - Google Patents

associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas

Info

Publication number
BR112015024920A2
BR112015024920A2 BR112015024920A BR112015024920A BR112015024920A2 BR 112015024920 A2 BR112015024920 A2 BR 112015024920A2 BR 112015024920 A BR112015024920 A BR 112015024920A BR 112015024920 A BR112015024920 A BR 112015024920A BR 112015024920 A2 BR112015024920 A2 BR 112015024920A2
Authority
BR
Brazil
Prior art keywords
healing
glutamine
hyaluronic acid
skin lesions
alanine
Prior art date
Application number
BR112015024920A
Other languages
English (en)
Inventor
Dechelette Corinne
Duplan Hélène
Bonzom Laetitia
Castex-Rizzi Nathalie
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of BR112015024920A2 publication Critical patent/BR112015024920A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers & Plastics (AREA)

Abstract

resumo patente de invenção: "associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas". a presente invenção refere-se a uma associação, compreendendo o dipeptídeo l-alanil -l-glutamina, o ácido hialurônico ou um de seus sais e um extrato de aveia, vantajosamente destinada à cicatrização e ao reparo das lesões cutâneas.
BR112015024920A 2013-04-10 2014-04-10 associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas BR112015024920A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353231A FR3004353B1 (fr) 2013-04-10 2013-04-10 Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees
PCT/EP2014/057224 WO2014167039A1 (fr) 2013-04-10 2014-04-10 Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees

Publications (1)

Publication Number Publication Date
BR112015024920A2 true BR112015024920A2 (pt) 2017-07-18

Family

ID=48741402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024920A BR112015024920A2 (pt) 2013-04-10 2014-04-10 associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas

Country Status (18)

Country Link
US (1) US9849154B2 (pt)
EP (1) EP2983691B1 (pt)
JP (1) JP2016515642A (pt)
KR (1) KR102202391B1 (pt)
CN (1) CN105101984B (pt)
AU (1) AU2014253131B2 (pt)
BR (1) BR112015024920A2 (pt)
CA (1) CA2908628C (pt)
DK (1) DK2983691T3 (pt)
ES (1) ES2661908T3 (pt)
FR (1) FR3004353B1 (pt)
HK (1) HK1212924A1 (pt)
MX (1) MX358845B (pt)
NO (1) NO2983691T3 (pt)
PL (1) PL2983691T3 (pt)
PT (1) PT2983691T (pt)
RU (1) RU2665371C2 (pt)
WO (1) WO2014167039A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3066693B1 (fr) 2017-05-24 2020-12-18 Fabre Pierre Dermo Cosmetique Composition pour le remodelage des cicatrices
KR101899413B1 (ko) * 2018-05-03 2018-09-18 주식회사 케어사이드 피부 감염의 예방 또는 치료용 조성물
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
KR102022400B1 (ko) * 2019-04-30 2019-09-18 (주)진셀팜 천연 복합 추출물을 유효성분으로 함유하는 안티폴루션 화장료 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368579B1 (en) * 2000-08-08 2002-04-09 Teresa Leigh Barr Oat protein complex sunblock and method of use
EP2656832B1 (en) * 2006-05-11 2018-12-19 Regenics AS Compositions for use in wound healing
FR2926461B1 (fr) * 2008-01-23 2010-03-05 Jean Noel Thorel Nouveau facteur de croissance cellulaire d'origine non animale et applications
FR2938439B1 (fr) 2008-11-14 2013-03-01 Fabre Pierre Dermo Cosmetique Extrait de parties aeriennes d'avoine recoltees avant epiaison
DE102009029813A1 (de) * 2009-06-18 2010-12-23 Henkel Ag & Co. Kgaa Antifalten-Kosmetikum
CN101816620B (zh) * 2010-03-12 2011-07-20 广州舒泰生物技术有限公司 一种美白化妆品及其制备方法和应用
MX2013000107A (es) * 2010-06-28 2013-06-03 Adetherapeutics Inc Tratamiento de queloides.
DE102010027180A1 (de) * 2010-07-14 2011-05-26 Henkel Ag & Co. Kgaa Nicht-therapeutische Verwendung zum Stammzellenschutz
JP2012240993A (ja) * 2011-05-24 2012-12-10 Q P Corp 肌弾力性改善剤
FR2977494B1 (fr) * 2011-07-08 2013-08-16 Ayawane Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes

Also Published As

Publication number Publication date
FR3004353A1 (fr) 2014-10-17
CA2908628A1 (fr) 2014-10-16
RU2665371C2 (ru) 2018-08-29
AU2014253131A1 (en) 2015-11-05
PT2983691T (pt) 2018-03-22
NO2983691T3 (pt) 2018-05-12
EP2983691B1 (fr) 2017-12-13
DK2983691T3 (en) 2018-03-19
US20160303181A1 (en) 2016-10-20
KR102202391B1 (ko) 2021-01-12
KR20150140319A (ko) 2015-12-15
US9849154B2 (en) 2017-12-26
FR3004353B1 (fr) 2015-05-15
PL2983691T3 (pl) 2018-05-30
CA2908628C (fr) 2021-06-08
MX2015014265A (es) 2016-03-01
RU2015142443A (ru) 2017-05-19
CN105101984A (zh) 2015-11-25
JP2016515642A (ja) 2016-05-30
MX358845B (es) 2018-09-05
ES2661908T3 (es) 2018-04-04
WO2014167039A1 (fr) 2014-10-16
CN105101984B (zh) 2018-06-01
HK1212924A1 (zh) 2016-06-24
EP2983691A1 (fr) 2016-02-17
AU2014253131B2 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
BR112015025854A2 (pt) flagelina de roseburia e modulação imunológica
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112015029611A2 (pt) composições para uso em ruptura de cartilagem
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
BR112015027536A8 (pt) composição compreendendo bactérias ácidas lácticas para utilização no tratamento preventivo e/ou curativo de cistite recorrente.
BR112014016808A8 (pt) composições de biguanida e métodos de tratamento de distúrbios metabólicos
BR112016006564A2 (pt) proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas
BR112015020209A2 (pt) uso de linagliptina em terapia antidiabética de proteção cardíaca e renal
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015015870A2 (pt) composição farmacêutica
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112014001268A2 (pt) peptídeos antifibróticos e seu uso em métodos para tratamento de doenças e distúrbios caracterizados por fibrose
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112015021931A2 (pt) Usos de composições farmacêuticas para prevenção e/ou tratamento de complicações do pulmão induzidas por radiação e da função pulmonar
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
BR112016003082A8 (pt) uso da tropoelastina na produção de um medicamento para cicatrização de uma ferida ou para melhora da reepitelização de uma ferida
BR112015024920A2 (pt) associação sinérgica da alanina-glutamina, o ácido hialurônico e um extrato de aveia e sua utilização em uma composição destinada à cicatrização e o reparo das lesões cutâneas
BR112015026388A2 (pt) métodos e composições para cicatrização de feridas
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
MX2018007871A (es) Composiciones para el cuidado personal.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.